157 related articles for article (PubMed ID: 83919)
41. [The leukocyte adherence inhibition test in diagnostics of malignancies (author's transl)].
Sarosiek J; Borejszo I
Przegl Lek; 1981; 38(7):561-5. PubMed ID: 7025111
[No Abstract] [Full Text] [Related]
42. Identification of a Mr 40,000 polypeptide from colorectal cancer which expresses organ-specific cancer neoantigen activity as determined by leukocyte adherence inhibition.
Artigas C; Thomson DM; Durko M; Sutherland M; Scanzano R; Shenouda G; Dubois AE
Cancer Res; 1986 Apr; 46(4 Pt 1):1874-81. PubMed ID: 2418955
[TBL] [Abstract][Full Text] [Related]
43. [Specific immunity in patients with carcinoma of the pancreas. Preliminary report].
Mester M; Zuliani A; Scheinberg MA; Machado MC
Rev Hosp Clin Fac Med Sao Paulo; 1983 Jun; 38(3):107-10. PubMed ID: 6364296
[No Abstract] [Full Text] [Related]
44. Cell-mediated immune reactions directed against syngeneic methylcholanthrene-induced mouse sarcomas: low reproducibility of the results obtained with the tube modification of leukocyte adherence inhibition assay.
Simová J; Bubeník J
Neoplasma; 1979; 26(5):635-9. PubMed ID: 392326
[TBL] [Abstract][Full Text] [Related]
45. Tumor-associated immunity and serum blocking by radioisotopic leukocyte adherence inhibition assay.
Tsang PH; Holland JF; Bekesi JG
Mt Sinai J Med; 1985 Mar; 52(3):193-200. PubMed ID: 3887140
[No Abstract] [Full Text] [Related]
46. Evaluation of micro-leukocyte adherence inhibition as an immunodiagnostic test for pancreatic cancer.
Goldrosen MH; Russo AJ; Howell JH; Leveson SH; Moore MC; Holyoke ED; Douglass HO
Cancer Res; 1979 Feb; 39(2 Pt 2):633-7. PubMed ID: 367589
[No Abstract] [Full Text] [Related]
47. Immune reactivity to Thomsen-Friedenreich antigen in patients with lung cancer detected by superoxide assay-leukocyte adherence inhibition test.
Ichinose Y; Yagawa K; Kaku M; Hara N; Ohta M
Cancer Res; 1985 Sep; 45(9):4473-7. PubMed ID: 2992780
[TBL] [Abstract][Full Text] [Related]
48. Extraction of human organ-specific cancer neoantigens from cancer cells and plasma membranes with 1-butanol.
Labateya N; Thomson DM; Durko M; Shenouda G; Robb L; Scanzano R
Cancer Res; 1987 Feb; 47(4):1058-64. PubMed ID: 3100029
[TBL] [Abstract][Full Text] [Related]
49. Characterization of murine tumor-associated antigens by the micro-leukocyte adherence inhibition assay.
Howell JH; Russo AJ; Goldrosen MH
Cancer Res; 1979 Feb; 39(2 Pt 2):612-8. PubMed ID: 83914
[No Abstract] [Full Text] [Related]
50. Leukocyte-mediated reactivity to human tumors as detected by the leukocyte adherence inhibition test. I. Demonstration of tumor type-specific reactions.
Hellström I; Hellström KE; van Belle G; Warner GA
Am J Clin Pathol; 1977 Nov; 68(5 Suppl):706-14. PubMed ID: 920666
[No Abstract] [Full Text] [Related]
51. Antigenic specificity and cellular mechanisms in leukocyte adherence inhibition analysis of immunity to simple proteins and hapten-protein conjugates.
Powell A; Sloss AM; Smith RN; Murrell H
Cancer Res; 1979 Feb; 39(2 Pt 2):570-5. PubMed ID: 83911
[TBL] [Abstract][Full Text] [Related]
52. Application of the indirect tube LAI assay in the study of cell-mediated immunity in rats immunized with B77 tumor cells.
Kalafut F; Hung PM; Novotná L; Klobusická M
Neoplasma; 1980; 27(5):525-31. PubMed ID: 7015159
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of the microleukocyte adherence inhibition assay as an immunodiagnostic test for pancreatic cancer.
Russo AJ; Douglass HO; Leveson SH; Howell JH; Holyoke ED; Harvey SR; Chu TM; Goldrosen MH
Cancer Res; 1978 Jul; 38(7):2023-9. PubMed ID: 77724
[No Abstract] [Full Text] [Related]
54. Problems in the clinical use of the microcytotoxicity assay for measuring cell-mediated immunity to tumor cells.
Heppner G; Henry E; Stolbach L; Cummings F; McDonough E; Calabresi P
Cancer Res; 1975 Aug; 35(8):1931-7. PubMed ID: 1149017
[TBL] [Abstract][Full Text] [Related]
55. Organ specific neoantigens reactive in the leukocyte adherence inhibition assay: affinity purification of human colon carcinoma antigen and its cross-reactive protein using monoclonal antibodies.
Hadas E; Fink A; Gembom E; Harpaz N; Shani A; Bentwich Z; Eshhar Z
Cancer Res; 1986 Oct; 46(10):5201-5. PubMed ID: 2428475
[TBL] [Abstract][Full Text] [Related]
56. [Modulating action of interferon preparations on cellular reactions of antitumor immunity].
Mkrtchian LN; Ter-Pogosian ZR; Sarkisian OM; Gevorkian RA; Movsesian EA
Vopr Onkol; 1983; 29(8):7-11. PubMed ID: 6351429
[TBL] [Abstract][Full Text] [Related]
57. [Anti-tumor immunity as measured by the tube leucocyte adherence inhibition assay (ALI)].
Fink A; Shani A; Bentwich Z
Harefuah; 1984 Jan; 106(2):86-7. PubMed ID: 6373516
[No Abstract] [Full Text] [Related]
58. [Effect of tumor antigens on leukocyte adherence in the blood in stomach cancer].
Zharkov VV; Novikov DK
Vopr Onkol; 1983; 29(2):14-8. PubMed ID: 6836968
[TBL] [Abstract][Full Text] [Related]
59. Use of leukocyte adherence inhibition test to study the cell mediated antitumour immunity in cancer patients.
Shirodkar SR; Gangal SG
Indian J Med Res; 1979 Jul; 70():88-96. PubMed ID: 387584
[No Abstract] [Full Text] [Related]
60. [Micromethod of the leukocyte adherence inhibition test with a fluorescence evaluation of the results].
Kurtenkov OA
Lab Delo; 1979; (1):11-3. PubMed ID: 83428
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
